Literature DB >> 33369527

Golimumab (anti-TNF monoclonal antibody): where we stand today.

Ana Teresa Melo1,2, Raquel Campanilho-Marques1,2, João Eurico Fonseca1,2.   

Abstract

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine and its overexpression has been implicated in the pathophysiology of several chronic immune-mediated inflammatory diseases. Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TNF monoclonal antibody that acts primarily by targeting and neutralizing TNF, thus preventing inflammation. It is approved for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Nonradiographic axial Spondyloarthritis, Juvenile Idiopathic Arthritis, and Ulcerative Colitis. Clinical trials are also being conducted in other conditions. This review charts the clinical development of golimumab and outlines the data that support its potential use across several Immune-mediated inflammatory diseases.

Entities:  

Keywords:  Immune-mediated inflammatory diseases; golimumab; tnf inhibitors

Mesh：

Substances：

Year:  2020        PMID： 33369527      PMCID： PMC8115761          DOI： 10.1080/21645515.2020.1836919

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  89 in total

1.  Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial.

Authors:  C C Mok; O C Li; K L Chan; L Y Ho; P K Hui
Journal:  Scand J Rheumatol       Date:  2015-08-14       Impact factor: 3.641

Review 2.  Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials.

Authors:  Pierre LE Blay; Gael Mouterde; Thomas Barnetche; Jacques Morel; Bernard Combe
Journal:  J Rheumatol       Date:  2012-03-01       Impact factor: 4.666

Review 3.  Tumor necrosis factor inhibitors in psoriatic arthritis.

Authors:  Santhi Mantravadi; Alexis Ogdie; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2017-05-22       Impact factor: 5.045

4.  The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn's Disease.

Authors:  Tomer Greener; Karen Boland; A Hillary Steinhart; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2018-03-28       Impact factor: 9.071

5.  A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.

Authors:  J Sieper; D van der Heijde; M Dougados; W P Maksymowych; B B Scott; J A Boice; Y Berd; G Bergman; S Curtis; A Tzontcheva; S Huyck; H H Weng
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

6.  Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.

Authors:  Hermine I Brunner; Nicolino Ruperto; Nikolay Tzaribachev; Gerd Horneff; Vyacheslav G Chasnyk; Violeta Panaviene; Carlos Abud-Mendoza; Andreas Reiff; Ekaterina Alexeeva; Nadina Rubio-Pérez; Vladimir Keltsev; Daniel J Kingsbury; Maria Del Rocio Maldonado Velázquez; Irina Nikishina; Earl D Silverman; Rik Joos; Elzbieta Smolewska; Márcia Bandeira; Kirsten Minden; Annet van Royen-Kerkhof; Wolfgang Emminger; Ivan Foeldvari; Bernard R Lauwerys; Flavio Sztajnbok; Keith E Gilmer; Zhenhua Xu; Jocelyn H Leu; Lilianne Kim; Sarah L Lamberth; Matthew J Loza; Daniel J Lovell; Alberto Martini
Journal:  Ann Rheum Dis       Date:  2017-05-15       Impact factor: 19.103

7.  Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.

Authors:  Alexandre Sepriano; Andrea Regel; Désirée van der Heijde; Jürgen Braun; Xenofon Baraliakos; Robert Landewé; Filip Van den Bosch; Louise Falzon; Sofia Ramiro
Journal:  RMD Open       Date:  2017-01-27

8.  Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.

Authors:  Arthur Kavanaugh; M Elaine Husni; Diane D Harrison; Lilianne Kim; Kim Hung Lo; Jocelyn H Leu; Elizabeth C Hsia
Journal:  Arthritis Rheumatol       Date:  2017-11       Impact factor: 10.995

9.  Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.

Authors:  Raphael J Dehoratius; Lawrence H Brent; Jeffrey R Curtis; Lorie A Ellis; Kezhen L Tang
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 10.  Golimumab for Rheumatoid Arthritis.

Authors:  Eleftherios Pelechas; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  J Clin Med       Date:  2019-03-20       Impact factor: 4.241
View more
  2 in total

1.  Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab.

Authors:  Tao Liu; Jin Xu; Qingcheng Guo; Dapeng Zhang; Jun Li; Weizhu Qian; Huaizu Guo; Xinli Zhou; Sheng Hou
Journal:  Front Chem       Date:  2022-04-05       Impact factor: 5.545

2.  Dexamethasone Alleviates Myocardial Injury in a Rat Model of Acute Myocardial Infarction Supported by Venoarterial Extracorporeal Membrane Oxygenation.

Authors:  Xingdong Cheng; Rongzhi Zhang; Shilin Wei; Jian Huang; Kerong Zhai; Yongnan Li; Bingren Gao
Journal:  Front Public Health       Date:  2022-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.